Prot #XmAb819-01: A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma

Project: Research project

Project Details

StatusActive
Effective start/end date4/11/25 → 4/11/28

Funding

  • ICON Clinical Research, LLC (Prot #XmAb819-01 // Prot #XmAb819-01)
  • Xencor, Inc. (Prot #XmAb819-01 // Prot #XmAb819-01)